Cloud-Clone adds four bone marrow primary cell products for niche research

Cloud-Clone Corp. launched a portfolio of four primary bone-marrow-derived cell products aimed at helping researchers study the bone marrow microenvironment. The new tools are positioned for work on osteoporosis, bone defects, hematological disease and pre-clinical cell therapy research.

Why it matters: - Bone marrow research depends on models that can better capture how cells interact in the niche. - Cloud-Clone’s four-cell portfolio is designed to help scientists study those interactions with primary cells that are functionally validated. - The products are aimed at research into osteoporosis, bone defects, hematological malignancies and other bone marrow-related diseases.

What happened: - Cloud-Clone introduced four primary bone-marrow-derived cell products. - The lineup includes bone marrow mesenchymal stem cells, bone marrow macrophages, bone marrow mononuclear cells and bone marrow endothelial progenitor cells. - The company said the products are available for global scientists working on basic and pre-clinical studies. - Researchers can find product listings and supporting materials on Cloud-Clone’s website.

The details: - Bone marrow mesenchymal stem cells are described as adherent, spindle-shaped adult stem cells with self-renewal and multi-lineage differentiation capacity. - BM-MSCs are presented as useful for orthopaedic tissue engineering, bone defect repair and cartilage regeneration. - The release says in-vitro BM-MSCs show more than 85% positive alkaline phosphatase staining after induction and strong type-I collagen staining. - BM-MSC-derived exosomes are said to promote cell proliferation, angiogenesis and tissue reconstruction through paracrine effects. - Bone marrow macrophages are framed as immune cells that support fracture healing and bone remodeling. - The release says bone marrow macrophages secrete BMP4, VEGF, IL-6 and CCL2 during inflammatory phases and help drive osteogenic differentiation. - Bone marrow mononuclear cells are described as a mixed population that includes hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor precursors, lymphocytes and monocytes. - BMMNCs can be isolated by density-gradient centrifugation using reagents such as Ficoll separation medium. - The cells are said to support work in angiogenesis, bone-defect repair, cell therapy and hematopoietic reconstitution. - The release says conventional endothelial progenitor cell preparations often contain CD45- and CD14-expressing monocytes/macrophages rather than true endothelial progenitors. - True endothelial colony-forming cells are described as having stronger proliferation, tube formation and in-vivo angiogenic capacity. - Cloud-Clone says its portfolio covers human, mouse, rat, rabbit, dog, cat, sheep, guinea pig and other species. - The company says the cells come from SPF-grade animal tissues and undergo phenotypic characterization and functional validation.

Between the lines: - The release reflects a broader shift in bone marrow research from single-cell assays toward multi-cell niche models. - The company is positioning its products around experimental fidelity, not just cell supply. - The EPC discussion also signals a practical message for researchers: cell labels can be less important than the isolation and sorting methods behind them.

What's next: - Cloud-Clone is directing researchers to its website for full product listings, characterization datasets and reference materials. - The company says the cell portfolio will support ongoing work in skeletal biology, hematology and regenerative medicine. - Cloud-Clone also points researchers to its other company information at More information.

The bottom line: - Cloud-Clone is betting that better primary bone marrow cell tools will help researchers model the niche more accurately and speed translational studies.